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Abstract
Diagnosis and treatment of comorbid conditions in hypertension are essential for efficient 
blood pressure control and for decreasing adverse clinical events and mortality. Sleep 
apnea, mainly its obstructive form, has a high prevalence both in the general population 
and in hypertensive patients, the main reason being the worldwide epidemic of obesity. 
This chapter summarizes the principal issues related to hypertension-sleep apnea rela-
tionship: definition of terms, epidemiological data and evidences, clinical manifestations 
of sleep apnea, pathophysiological background of the adverse effects of sleep apnea on 
the cardiovascular system, screening and definitive diagnosis, and the effects of specific 
and nonspecific sleep apnea interventions on hypertension.
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1. Introduction
Cardiovascular and non-cardiovascular comorbidities are frequently present in the setting of 
hypertension. Usually, they influence adversely the clinical course and treatment; thus, their 
identification (diagnosis) and management is mandatory. In this regard, sleep apnea, due to 
its high prevalence and the multiple ways it could affect the patients, is considered one of the 
most important non-cardiovascular comorbidities in hypertension [1, 2].
2. Definitions, quantification of sleep apnea
Sleep apnea (SA) is a sleep-related breathing phenomenon and consists of the involuntary 
cessation (or near cessation, >90%) of airflow to the lungs for at least 10 seconds. SA takes part 
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from the large family of sleep disorders, being the most important manifestation of sleep-
related breathing disorders (“sleep disordered breathing”). The latter entity also comprises 
the sleep-related hypoventilation syndromes, their most frequently occurring form, the obe-
sity hypoventilation syndrome, being also present (with or without SA) in some patients with 
hypertension and/or metabolic syndrome [3, 4].
While apnea is the most characteristic and important phenomenon, there also exist other 
respiratory events related to sleep, which have to be considered. Hypopnea represents an 
at least 30% reduction of airflow for 10 seconds from the pre-event baseline, associated with 
3% oxygen desaturation and/or an arousal signal on the EEG, or, alternatively, a 4% oxygen 
desaturation (the arousal being not mandatory in this case) [3, 4].
Respiratory effort-related arousals (RERAs), lasting at least 10 seconds, are induced by airflow 
limitation (increased upper airways resistance), which do not fulfill the criteria for apnea or 
hypopnea. In fact, increased upper airways resistance, hypopnea, and apnea represent a con-
tinuum and denote progression of the of the sleep-related upper airways obstruction [3, 4].
The most used parameter for the quantification of SA is the so-called apnea-hypopnea index 
(AHI), which represents the number of (apneas + hypopneas)/hour of sleep and is determined 
more exactly by polysomnography (PSG). The AHI is <5 normally, and the SA is consid-
ered significant if the AHI is ≥15. An AHI ≥ 30 heralds a severe SA. Another approach of 
quantification uses the respiratory disturbance index (RDI), which represents the number of 
(apneas + hypopneas + RERAs)/hour of sleep. In the case of home sleep apnea testing (HSAT), 
the devices used are not capable of EEG recording (which identifies the sleep phases and 
arousals); thus, the American Academy of Sleep Medicine (AASM) recommends the term 
“respiratory event index” (REI) instead of AHI or RDI. In this case, the number of sleep hours 
is replaced by the number of recording hours. On the other hand, different indices of the 
degree of hypoxemia occurring during sleep could also be calculated—hypoxemic burden, 
oxygen desaturation index, average oxygen saturation, etc. [3–6].
Obstructive sleep apnea (OSA) is a form of SA, when the lack of airflow is caused by the collapse 
of the upper airways (mainly at the level of oropharynx) and the—inefficient—respiratory 
 movements are maintained during apnea/hypopnea (similarly to forced inspiration against 
a closed glottis = Müller’s maneuver). An arousal reaction with or without awakening re-
establishes the normal breathing. OSA is the typical form of SA encountered in the setting of 
hypertension.
In the case of central sleep apnea (CSA), the malfunction of the respiratory center and the 
lack of efferent impulses to respiratory muscles cause the airflow cessation. A specific form of 
CSA is the so-called periodic or Cheyne-Stokes respiration (CSR), with breathing “spindles” 
(gradually increasing and decreasing breathing amplitudes) between apneas. CSA and CSR 
are characteristic in hypertension only if congestive heart failure or cerebral lesions (e.g., post-
stroke status), the main determinants of the appearance of CSA, are present as associated con-
ditions. Mixed (obstructive + central) SA could also occur in patients with hypertension [2, 3].
Because of its high prevalence and clinical importance in hypertension, in the following, 
mainly data related to OSA will be presented.
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3. Epidemiological data and evidences regarding the close relationship 
between OSA and hypertension
The prevalence of OSA (AHI ≥ 5 and the presence of at least one symptom induced by altered 
sleep) in the general population is high, especially because of the increasing occurrence of 
obesity. Roughly, 20–30% of men and 10–15% of women suffers from OSA. Significant OSA 
(moderate or severe, with AHI ≥ 15) is present in about 15% of males and 5% of females. 
However, there is a concern regarding underestimation of the real prevalence of OSA espe-
cially in women, who frequently have atypical symptoms. The prevalence increases with 
advancing age, race, ethnicity (African Americans and Hispanics) and body mass index [7, 8].
There exists a large amount of epidemiological data and evidences regarding the bidirectional, 
complex relationship between OSA and hypertension. The prevalence of OSA in hypertensive 
patients is about 30–50%, while hypertension is present in OSA patients in about 50%. The 
relationship between the prevalence/severity of OSA and the grade of hypertension is almost 
linear. The best example for this fact serves the case of resistant hypertension, when the preva-
lence of any OSA is about 80%, while the presence of moderate or severe OSA reaches 56% 
[2, 9–11]. Relative to other hypertensive patients, the risk of OSA is 2.5-fold increased in 
patients with resistant hypertension, and, in the same time, OSA is more severe in patients 
with resistant hypertension than in those without [12].
Despite of the existence of potential confounders, like obesity, age, sex, metabolic syndrome, 
and diabetes mellitus, epidemiological data clearly demonstrate the independent association 
between OSA and incident and prevalent hypertension [13–15].
4. Risk factors of OSA, clinical manifestations, and nocturnal 
clinical events
Epidemiological data consistently support the existence of risk factors of developing and pro-
gression of OSA. These risk factors contribute to the anatomical and/or functional narrowing 
of the upper airways (e.g., fat deposition in the surrounding tissues in obesity), enhancing 
their susceptibility to collapse [16].
The principal risk factors of OSA are age, male gender, obesity, and abnormalities of the upper 
airways and craniofacial structures (especially in Asian subjects) [17]. Obesity and overweight 
could be considered the most important risk factors due to their high prevalence both in patient 
with OSA and hypertension. Also, the increasing tendency of obesity in the general popula-
tion could be considered as the main responsible for the continuously increasing prevalence of 
both OSA and hypertension. A 10% increase in body mass is associated with a sixfold increase 
in risk of incident OSA, and, in a population-based study, moderate to severe OSA (AHI ≥15) 
was present in 63%/22% (male/female) of patients with BMI ≥30 kg/m2 [17–21].
Other important risk factors of OSA include smoking, alcohol use, sedative or narcotic intake 
before sleep, nasal obstruction, menopause, and family history (for snoring or OSA).
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The prevalence of OSA was found to be increased in association with some medical con-
ditions, such as pregnancy, congestive heart failure, chronic pulmonary disease (asthma, 
chronic obstructive pulmonary disease, pulmonary fibrosis), end-stage kidney disease, 
stroke, and endocrine disorders (hypothyroidism, acromegaly, polycystic ovary syndrome) 
[16, 17, 22].
The main clinical manifestations of OSA are presented in Table 1. Diurnal symptoms are the 
consequences of the insufficient, fragmented, low-quality sleep caused by multiple arousals 
induced by apnea. The complex pathophysiology of the nocturnal clinical events will be pre-
sented in detail later.
5. Pathophysiological basis of sleep apnea-hypertension relationship
The complex pathophysiological mechanisms behind acute clinical events and chronic medical 
conditions, including hypertension, induced and/or aggravated by OSA, are presented in Table 2.
The most important mechanisms related to OSA that play a role in the genesis and pro-
gression of hypertension are the long-term activation of the sympathetic nervous system 
and the renin-angiotensin-aldosterone system. Also, during arousals, the acute sympathetic 
Nocturnal symptoms Diurnal symptoms
Heavy, loud snoring
Restless, interrupted sleep
Awakenings with choking, gasping
Insomnia
Observed apneas by sleep partner
Nocturia
Sweating
Dry mouth
Acid reflux
Morning headache and dizziness
Feeling of an inadequate, unrestful sleep
Excessive sleepiness with/without episodes of 
involuntary
Tiredness, falling asleep (e.g., causing car accidents)
Attention, memory, and cognition deficits
Decreased performance at school, workplace, etc.
Mood disorders: depression, anxiety
Sexual dysfunction: loss of libido, impotence
Nocturnal clinical events
Myocardial ischemia—silent, angina, myocardial infarction
Arrhythmias—bradycardias, supraventricular arrhythmias, atrial fibrillation, ventricular arrhythmias, sudden 
cardiac death
Blood pressure ascensions
Acute cardiac decompensation (left and/or right heart failure)
Stroke (ischemic, hemorrhagic)
Table 1. Nocturnal and diurnal symptoms and nocturnal clinical events related to OSA [2, 22, 23].
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Pathophysiological mechanism Consequences
Hypoxemia
Hypercapnia
Repetitive hypoxia-normoxia 
cycles
(also present in CSA)
1. Ischemia (myocardial, cerebral, etc.)
2. Bradycardia (during apnea)—tachycardia (caused by arousal)
3. Oxidative stress and systemic inflammatory reaction
• Endothelial dysfunction—accelerated atherosclerosis
4. Hypoxic pulmonary vasoconstriction
• Acute and chronic increase of pulmonary arterial pressure with right ven-
tricular overload
5. Decreased baroreflex activity—contributing to hypertension
6. Activation of the sympathetic nervous system due to increased chemoreflex 
sensitivity
• Hypertension (acute and chronic)
• Sinus tachycardia
• Arrhythmias
• Ischemia (increased oxygen demand)
• Cardiac toxicity and remodeling (e.g., hypertrophy)
• Endothelial dysfunction—accelerated atherosclerosis
• Insulin resistance, metabolic syndrome
7. Activation of the renin-angiotensin-aldosterone system
Arousals (with or without 
awakenings) (also present in CSA)
1. Acute activation of the sympathetic nervous system and withdrawal of the 
parasympathetic cardiac control
Negative intrathoracic pressure 
during inspiratory effort (only in 
OSA)
1. Increased transmural pressure of cardiac cavities, great vessels, and pulmonary 
arterial bed
• Increased left and right ventricular afterload
 ○ Acute and chronic cardiac decompensation
 ○ Ischemia (increased oxygen demand)
 ○ Arrhythmias
• Atrial dilation—favoring atrial fibrillation
• Aortic dilation
• Pulmonary fluid retention, contributing to acute cardiac  
decompensations
Table 2. Pathophysiological mechanisms and their consequences in the setting of OSA [2, 23, 24].
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hyperactivation causes blood pressure increases, which could precipitate acute cardiac 
decompensation, myocardial ischemia, arrhythmias, or stroke.
The characteristics of hypertension in the case of significant OSA as comorbidity are the high 
blood pressure values during nighttime (nocturnal blood pressure surge) and the concomi-
tant non-dipping behavior of 24-hour values. Also, blood pressure variability is increased and 
heart rate variability is blunted, as markers of cardiac autonomic dysfunction. The control of 
blood pressure values could be difficult in many cases, development of resistant hypertension 
with target organ damage (e.g., left ventricular hypertrophy) being the rule [25, 26].
Masked hypertension was also found to be more prevalent in patients with OSA; in one study 
30% of newly diagnosed OSA patients had masked hypertension [27].
In patients with hyperaldosteronism, there is a higher prevalence of OSA (1.8 times). Fluid 
retention induced by aldosterone and its redistribution to the neck tissues is a major contribu-
tor to this finding. This mechanism (a vicious circle) contributes significantly to the higher 
prevalence of coexisting resistant hypertension and severe OSA in these patients [28].
Experimental and human studies data support that the relationship between hypertension 
and OSA is bilateral. Blood pressure increases, by baroreceptor activation, could inhibit the 
upper airways muscle tone, enhancing their tendency to collapse [29].
6. Diagnosis of SA in clinical practice
The diagnosis of SA in hypertensive patients does not differ from those without hyperten-
sion. The diagnostic approach has two main elements: screening and confirmation (definitive 
diagnosis).
First, screening is mandatory when significant nocturnal and/or diurnal symptoms are pres-
ent in a patient. These could be observed or find out by the patient itself, by his/her bed 
partner, or by different surrounding persons (including the medical personnel). The most 
important symptoms in this regard are heavy snoring, restless sleep, awakenings associated 
with choking, witnessed apnea, and excessive daytime sleepiness. Also, screening is recom-
mended if pronounced risk factors or certain clinical conditions are present: severe obesity, 
hardly controllable, resistant hypertension (usually with target organ damage and non-dip-
ping 24-hour pattern), frequent nocturnal palpitations or proven nighttime arrhythmias, atrial 
fibrillation recurrence(s) after cardioversion(s), therapy refractory heart failure or frequent 
decompensations, “unexplained” pulmonary hypertension and right ventricular overload, 
and nocturnal stroke without an overt etiology [2, 5].
The most used screening tools are the comprehensive sleep evaluation, the sleep apnea ques-
tionnaires, and the overnight pulse oximetry. The latter method consists of a demonstration 
of oxygen desaturations (an indirect measure of SA) during the night. It cannot differentiate 
the obstructive and central apneas.
There are multiple validated (against PSG and HSAT) sleep questionnaires, morphometric 
and clinical prediction models which are based on the testing of the presence of the most 
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important symptoms and features related to SA/OSA. The most used are the Epworth’s, 
Berlin, and STOP-BANG questionnaires. The Epworth Sleepiness Scale (moderate sensitiv-
ity, good specificity) involves eight questions to assess excessive daytime sleepiness [5, 30, 
31]. The Berlin questionnaire (good sensitivity, moderate specificity) uses eleven questions 
(from three categories) to determine the risk of patient for OSA [5, 31, 32]. The STOP-BANG 
questionnaire (high sensitivity and good specificity) is a more and more popular tool for OSA 
screening and is based on four yes/no questions and on four clinical features (Table 3) [5, 31, 
33, 34]. Current guidelines recommend against using any screening tool to diagnose OSA in 
adults, in the absence of PSG or HSAT [5].
The definitive diagnosis of SA is always device-based. Every patient with high clinical suspi-
cion of SA, based on a comprehensive sleep evaluation, screening tools, and/or the presence 
of the cardinal symptoms of OSA (excessive daytime sleepiness and at least two of the follow-
ing: loud snoring, witnessed apnea or gasping or choking, diagnosed hypertension), has to 
undergo overnight sleep monitoring [5].
1. Snoring?
Do you snore loudly (loud enough to be heard through closed doors or your bed partner elbows you 
for snoring at night)?
2. Tired?
Do you often feel tired, fatigued, or sleepy during the daytime (such as falling asleep during driving 
or talking to someone)?
3. Observed?
Has anyone observed you stop breathing or choking/gasping during your sleep
4. Pressure?
Do you have or are being treated for high blood pressure?
Yes/No
5. Body mass index more than 35 kg/m2?
6. Age older than 50?
7. Neck size large? (measured around Adam’s apple)
For male, is your shirt collar 17 inches/43 cm or larger?
For female, is your shirt collar 16 inches/41 cm or larger?
8. Gender = Male?
Yes/No
OSA—Low risk: Yes to 0–2 questions
OSA—Intermediate risk: Yes to 3–4 questions
OSA—High risk: Yes to 5–8 questions
or Yes to 2 or more of 4 STOP questions + male gender
or Yes to 2 or more of 4 STOP questions + BMI > 35 kg/m2
or Yes to 2 or more of 4 STOP questions + neck circumference 17 inches/43 cm in male or 16 inches/41 cm in female
Table 3. The STOP-BANG questionnaire and its evaluation.
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The diagnostic devices are categorized as Type I to IV depending on the number of biological 
signals (channels) monitored. PSG represents the gold standard of sleep monitoring, having 
the capability to register the following channels: EEG, EOG, ECG/heart rate, chin EMG, limb 
EMG, respiratory effort at thorax and abdomen, airflow from a nasal cannula, pulse oximetry, 
etc. (a minimum of 7 channels). PSG could be used for Type 1 (attended, in the sleep labora-
tory) and Type 2 (unattended, at home) sleep studies. In the case of HSAT, as a rule, Type III 
Figure 1. A typical registration with a Type III sleep monitor from a patient with OSA. SpO2—oxygen saturation, HR—
heart rate, flow—nasal airflow, effort—chest movements (maintained during apneas).
Figure 2. A typical registration with a Type III sleep monitor from a patient with CSA. Airflow—nasal airflow; CHTM, 
ABDM—chest and abdominal movements (absents during apneas); SNORE—snoring; SpO2—oxygen saturation; 
pulse—heart rate.
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devices with minimum 4 channels (airflow, respiratory movements, pulse oximetry—heart 
rate; optionally: ECG, body position, snoring, etc.) are used. In Figures 1 and 2 typical record-
ings, using a Type III device, are presented from a patient with severe OSA and from another 
with severe CSA. The portable, Type III devices used for HSAT have the disadvantage vs. 
PSG, that they do not monitor the sleep itself (lack of EEG, EOG, EMG) and do not provide 
real-time data with the possibility of on-line corrections of monitoring. Due to these facts, and 
to the relatively frequent measurement artifacts, patients with equivocal sleep monitoring 
results have to undergo a standard, attended PSG in the sleep laboratory [5, 6, 35].
Current recommendations of the AASM regarding the diagnostic use of PSG and HSAT are 
presented in Table 4.
7. The effect of OSA interventions on comorbid hypertension
Complex treatment of moderate/severe OSA is mandatory in the setting of hypertension, the 
expected results being a better quality of life of the patients and a more efficient blood pres-
sure control.
The control of modifiable factors which contribute to both conditions—reducing obesity, 
smoking, and alcohol consumption—is considered a very effective, first step treatment 
modality of comorbid OSA and hypertension [23, 24, 36].
The standard and efficient device-based therapy of OSA consists of the utilization of continu-
ous positive airway pressure (CPAP). In the literature, there are a plenty of studies, usually 
Recommendation statement Strength of 
recommendation
1. We recommend that clinical tools, questionnaires, or prediction algorithms not be used 
to diagnose OSA in adults, in the absence of PSG or HSAT
Strong
2. We recommend that PSG, or HSAT with a technically adequate device, be used for the 
diagnosis of OSA in uncomplicated adult patients presenting with signs and symptoms 
that indicate an increased risk of moderate to severe OSA
Strong
3 We recommend that if a single HSAT is negative, inconclusive or technically 
inadequate, PSG be performed for the diagnosis of OSA
Strong
4. We recommend that PSG, rather than HSAT, be used for the diagnosis of OSA in 
patients with significant cardiorespiratory disease, potential respiratory muscle 
weakness due to neuromuscular condition, awake hypoventilation or suspicion of 
sleep-related hypoventilation, chronic opioid medication use, history of stroke, or 
severe insomnia
Strong
5. We suggest that, if clinically appropriate, a split-night diagnostic protocol, rather than a 
full-night diagnostic protocol for PSG, be used for the diagnosis of OSA
Weak
6. We suggest that when the initial PSG is negative, and there is still clinical suspicion for 
OSA, a second PSG be considered for the diagnosis of OSA
Weak
Table 4. Current recommendations of the AASM regarding the use of PSG and HSAT for diagnosing OSA [5].
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sham-CPAP controlled, concerning the impact of CPAP treatment on comorbid hypertension 
with diverse grades. The results of these studies, sometimes contradictory, are presented and 
commented in detail in recent meta-analyses and critical reviews [37, 38, 39]. The effects of 
CPAP treatment on blood pressure (hypertension) in OSA patients could be summarized as 
follows: (1) prehypertension and masked hypertension are reduced [40], (2) there is a clear 
tendency of decreasing both the nighttime and daytime blood pressure values (but only mod-
est reductions, generally 2–5 mmHg), (3) there is a slight reversal of the non-dipping behavior, 
and (4) the effect of CPAP treatment seems to be more pronounced if there is a good treat-
ment adherence (use of the device at least 5 hours/night), the patient is more symptomatic, and 
the OSA and/or hypertension are more severe [37, 38, 39]. As a conclusion, CPAP treatment 
in comorbid OSA and hypertension is a relatively modest, but efficient, additive modality of 
controlling blood pressure values. The beneficial effects of CPAP treatment are the results of 
reducing sympathetic overactivity by controlling hypoxemia, arousals, and negative intratho-
racic pressure.
Oral appliance therapy, a treatment option in mild and moderate forms of OSA, also could 
improve blood pressure control in the case of concomitant hypertension [41, 42].
Regarding the effect of antihypertensive drugs on OSA in hypertensive patients, the (some-
times conflicting) data do not support clearly a specific beneficial effect of the usually pre-
scribed drugs (angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, 
calcium-channel blockers, diuretics, beta-blockers) [23, 24]. However, hypertensive patients 
with hyperaldosteronism and those with resistant hypertension could benefit from spirono-
lactone as first choice therapy, with proven beneficial effects on OSA. Generally, diuretics by 
reducing fluid retention, including that at the level of parapharyngeal tissues, could amelio-
rate upper airway obstruction and OSA [43, 44].
8. Conclusion
Hypertension and SA, especially OSA, are frequently associated, and there is a well-documented 
pathophysiological link between OSA and development and aggravation of hypertension. 
Screening and diagnosis of OSA is mandatory whenever increased nocturnal and daytime 
symptoms and/or difficult to control hypertension (resistant, as a rule, with high nocturnal 
blood pressure values and target organ damages) is present. The treatment of OSA by specific 
(e.g., CPAP) or nonspecific means could contribute significantly to a better quality of life of 
the patients, to a better control of blood pressure values, and to the decrease of OSA-related 
adverse clinical events.
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